Your Heart Patients Are Losing Their Nerves — Literally
Every February, the healthcare community turns its attention to cardiovascular disease — and rightfully so. But as a provider managing patients with hypertension, diabetes, atherosclerosis, and other cardiovascular risk factors, there's a downstream consequence you may be seeing in your practice more than you realize: peripheral neuropathy.
The clinical overlap between cardiovascular disease and peripheral neuropathy is significant, well-documented, and frequently under addressed. For providers looking to deliver more comprehensive care — and differentiate their practice — this connection represents both a clinical opportunity and a growth opportunity.
The Cardiovascular-Neuropathy Pipeline
The pathophysiology is straightforward. Your cardiovascular patients are at elevated risk for peripheral neuropathy because the same mechanisms driving their heart disease are simultaneously destroying peripheral nerve fibers.
Diabetes and metabolic syndrome remain the most prominent shared risk factor. Chronically elevated blood glucose damages the vasa nervorum — the small blood vessels that supply peripheral nerves — while simultaneously causing direct oxidative damage to nerve fibers. Up to 70% of diabetic patients develop some form of neuropathy, and these are the same patients filling your cardiovascular risk panels.
Hypertension accelerates microvascular damage throughout the body, reducing perfusion to peripheral nerves long before patients report symptoms. By the time a patient presents with numbness or tingling in the extremities, the underlying nerve degeneration may be well advanced.
Atherosclerosis and peripheral artery disease restrict macrovascular blood flow to the extremities, compounding the microvascular damage. Patients with PAD have significantly higher rates of neuropathy — yet neuropathy screening in this population remains inconsistent across most practices.
Chronic systemic inflammation — elevated CRP, IL-6, TNF-alpha — is a known driver of both cardiovascular events and demyelination of peripheral nerves. The inflammatory cascade doesn't discriminate between vascular endothelium and nerve tissue.
The Clinical Gap You're Likely Seeing
Here's what this looks like in practice: patients come in for cardiovascular management and mention — almost as an afterthought — that their feet have been numb, they're experiencing burning pain at night, or they've been losing balance. Many have already been told that neuropathy is just something they'll have to live with. Some are on gabapentin or pregabalin with marginal relief and unwanted side effects.
The reality is that peripheral neuropathy affects an estimated 20 million Americans, and the majority of those patients have overlapping cardiovascular risk factors. They're already in your practice. They're already your patients. They're just not getting a solution for this particular problem — because until recently, there hasn't been a compelling one to offer.
Where Neurogenx Fits In
The Neurogenx Treatment is an FDA-cleared, non-surgical, drug-free therapy that uses advanced electroanalgesic technology to address peripheral neuropathy at the nerve level — not just at the symptom level.
For providers managing cardiovascular patients, this matters for several practical reasons:
No pharmaceutical interactions. The treatment is entirely non-pharmaceutical, which eliminates concerns about drug interactions with anticoagulants, antihypertensives, statins, or other cardiac medications your patients are already managing. This is a significant advantage over pharmacological neuropathy interventions.
Clinically documented nerve regeneration. This isn't just pain management. Independent laboratory studies have documented nerve density increases averaging 165.4%, with cases showing improvements up to 395%. These are measurable, objective outcomes — nerve fiber regeneration confirmed through skin biopsy analysis.
87% patient success rate. Clinical data shows that 87% of patients treated with Neurogenx experience significant symptom improvement. For a patient population that has often been told nothing can be done, these outcomes drive exceptional patient satisfaction and referral generation.
Turnkey practice integration. Neurogenx provides comprehensive support for practices adding neuropathy treatment — including staff training, marketing support, and operational guidance. The program is designed to generate revenue without requiring significant overhead or workflow disruption.
The Business Case for Your Practice
Beyond the clinical rationale, there's a compelling practice growth argument. Neuropathy treatment is a high-demand, low-competition specialty in most markets. Patients are actively searching for solutions — and most are finding limited options.
Adding a Neurogenx neuropathy program allows your practice to:
Serve existing patients more comprehensively by addressing a condition many of them are already living with
Attract new patients seeking neuropathy treatment who may also need cardiovascular management
Create a recurring revenue stream through a structured treatment protocol
Differentiate from competitors who are limited to pharmaceutical management of neuropathy symptoms
For practices already managing cardiovascular populations, the patient acquisition cost is effectively zero — these patients are already on your schedule.
This February: Think Beyond the Heart
American Heart Month is an ideal time to evaluate how comprehensively your practice is serving cardiovascular patients. If you're managing their blood pressure, their cholesterol, and their blood sugar — but not addressing the peripheral neuropathy that's eroding their quality of life — there's a gap in care that Neurogenx can help you close.
The patients are already in your practice. The clinical need is already there. The question is whether your practice is positioned to meet it.
Learn how Neurogenx can integrate into your practice.
Contact Neurogenx at 1 (800) 335-7624 or visit neurogenx.com to schedule a consultation and learn about current provider programs.
